+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin use in patients with diabetes and kidney disease: the Japanese experience



Statin use in patients with diabetes and kidney disease: the Japanese experience



Journal of Atherosclerosis and Thrombosis 20(5): 407-424



Diabetes is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in developed nations, including Japan and the United States. Japan has the unenviable distinction of having one of the world's highest rates of dialysis: in 2011, there were over 300,000 dialysis patients (2,383 per million people), with diabetic patients accounting for almost half of all incident cases. Concomitance of CKD and diabetes predicts a greater risk of cardiovascular disease (CVD) than either condition in isolation. Hence, appropriate management of modifiable cardiovascular (CV) risk factors, including dyslipidemia, is paramount in this high-risk group. The United States and Japan have distinct approaches to cholesterol management, with more stringent therapeutic targets for lipid control advocated in US guidelines. However, upward trends in cholesterol levels and coronary heart disease incidence in Japan may provide justification for more intensive CV risk factor management strategies by Japanese physicians to achieve maximum benefit. Attainment of recommended lipid goals in Japan is poor, particularly in patients with diabetes and/or CKD in whom CV risk factors are often undertreated. Statin therapy has been shown to be safe and effective in reducing CV risk in patients with diabetes and/or CKD stages 1-5. Moreover, statins may impart a renoprotective effect by preventing or delaying progressive loss of kidney function. This review summarizes evidence from studies in Western and Japanese populations to highlight the CV and renal benefits of lipid-lowering agents in CKD patients, including those with diabetes.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911490

Download citation: RISBibTeXText

PMID: 23518468

DOI: 10.5551/jat.16261


Related references

RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease 12(): 142-142, 2014

A cross-sectional survey of chronic kidney disease and diabetic kidney disease in Japanese type 2 diabetic patients at four urban diabetes clinics. Internal Medicine 48(6): 411-414, 2009

Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Therapeutic Advances in Cardiovascular Disease 7(6): 306-315, 2014

Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. Nutrition Journal 12(): 159-159, 2014

Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice 99(2): 145-150, 2013

Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice 84(1): 39-45, 2009

The self-management experience of patients with type 2 diabetes and chronic kidney disease: A qualitative study. Chronic Illness 12(1): 18-28, 2015

Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes. Clinical Chemistry and Laboratory Medicine 50(10): 1833-1839, 2013

Should all patients with chronic kidney disease take a statin?. Cleveland Clinic Journal of Medicine 75(2): 118-120, 2008

Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes. Diabetic Medicine 27(9): 1017-1023, 2011

Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart and Vessels 29(1): 21-28, 2014

The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications 26(4): 286-290, 2013

Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease. Disease Markers 2015(): 252564-252564, 2016

Statin therapy in patients with chronic kidney disease: to use or not to use. European Journal of Clinical Investigation 36(8): 519-527, 2006

Statin use and sepsis in patients with chronic kidney disease. JAMA 298(3): 284; Author Reply 284-5, 2007